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Dyskinesias are involuntary muscle movements that occur spontaneously in Huntington’s disease (HD) and after long-term
treatments for Parkinson’s disease (levodopa-induced dyskinesia; LID) or for schizophrenia (tardive dyskinesia, TD). Previous
studies suggested that dyskinesias in these three conditions originate from different neuronal pathways that converge on
overstimulation of the motor cortex. We hypothesized that the same variants of the N-methyl-D-aspartate receptor gene that were
previously associated with the age of dyskinesia onset in HD were also associated with the vulnerability for TD and not LID.
Genotyping patients with LID and TD revealed, however, that these two variants were dose-dependently associated with
susceptibility to LID, but not TD. This suggested that LID, TD and HD might arise from the same neuronal pathways, but TD
results from a different mechanism.
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Introduction
Dyskinesias are involuntary muscle movements that occur as
a symptom of Huntington’s disease (HD), but also as a
complication of long-term treatment with antipsychotic drugs
(tardive dyskinesia, TD) or levodopa in Parkinson’s disease
(on-off phenomena, levodopa-induced dyskinesia, LID).1–4 In
HD, these involuntary movements have been linked to
degeneration of a specific subtype of striatal medium-sized
spiny neurons (MSNs) that constitute part of the indirect
pathway of the extrapyramidal circuit (Figure 1).5–7 Stimula-
tion of these indirect pathway MSN by cortico-striatal
glutamatergic neurons results in inhibition of cortical motor
areas at the end of this circuit (hypokinesia).8 In contrast to
dyskinesias in HD, LID is believed to be induced by dopamine
D1 receptor bearing direct pathway MSN.4 Pulsatile stimula-
tion of these D1 receptors may cause long-term potentiation at
N-methyl-D-aspartate (NMDA) receptor of corresponding
cortico-striatal synapses, which results in overactivity of the
direct pathway MSNs. This leads to activation of cortical areas
at the end of this circuit (hyperkinesia).8 The mechanism
underlying TD is not well understood. This movement disorder
occurs after long-term treatment with D2 receptor antagonists
and is believed to be caused by damage of the D2 receptor
bearing indirect pathway MSNs. It has been hypothesized that
this damage is caused by the formation of free radicals
induced by long-term treatment.9 However, treatment with the
antioxidant, vitamin E, did not have convincing effects on TD.9
Alternatively, Konitiostis and others reported that NMDA
antagonists showed therapeutic effects in an animal model
of TD.10 Recently, two independent research groups have
shown that presence of a specific variant of the NMDA
receptor subunit gene is strongly related to the age of onset of
dyskinesias in HD.11–13 These variants could increase the
vulnerability to develop dyskinesia by increasing the sensitiv-
ity of indirect pathway MSN to excitotoxicity. As TD is also
believed to be related to toxicity at indirect pathway MSN,
these variants might also increase the likelihood to develop
TD. LID is believed to be related to increased sensitivity
of cortico-striatal synapses with direct pathway MSN, and
expected to be independent of excitotoxicity at indirect
pathway MSN. We therefore hypothesized that these variants
might be associated with the likelihood to develop TD and not
LID. Our results, to our surprise, are opposite to this
hypothesis and make us to question the role of direct pathway
MSN in LID.
Subjects and methods
Patients. In order to test our hypotheses about the role
of the abovementioned NMDA receptor variants in TD and
LID, we examined a total of 574 Caucasian patients
(Supplementary Table 1). Of them, 431 were from three
psychiatric hospitals in Tomsk, Kemerovo and Chita oblasts
in Siberia. These patients demonstrated schizophrenia (N¼ 401,
95.1%) or schizotypical disorders according to ICD-10 criteria.
All these patients were on long-term treatment with anti-
psychotic drugs. For comparison, antipsychotic medication
doses were converted into chlorpromazine equivalents.14
Patients were assessed for the presence or absence of
dyskinesia, according to the abnormal involuntary movement
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scale (AIMS).15 The AIMS scores were transformed into a
binary form (presence or absence of dyskinesia) with Schooler
and Kane’s criteria.16 In addition, a blood sample was taken for
DNA isolation and genotyping. We also examined 143
patients with spontaneous extrapyramidal disorders (101
(70.6%) of them had Parkinson’s disease, 21 (14.7%) had
dystonia, 21 had tremor) from the neurology department of
the Siberian State Medical University of Tomsk. These
patients had not been treated with dopamine antagonists
(antipsychotic or antiemetic drugs) for at least 3 years. Of
both the groups, other inclusion criteria were no addictions,
no current clozapine treatment, no organic disorders and a
high quality DNA sample.
DNA analysis. DNA extraction and the Veracode Assay
were conducted according to standard protocols. Apart from
the to-be studied variants of the genes that encoded two
subunits of the glutamatergic NMDA receptor, NR2A and
NR2B (GRIN2A and GRIN2B, respectively), we selected a
subset of informative SNPs, or tag SNPs, that would
accurately represent the majority of SNPs for these genes.
The selection method was previously described by Xu
and Taylor (freely available at http://www.niehs.nih.gov/
snpinfo).17 We selected only tag SNPs that captured at
least 10 SNPs, including finally 15 SNPs that covered the
GRIN2A gene and 9 that covered the GRIN2B gene. For
comparison, we also selected a set of variants of 6 unrelated
genes that have been reported to be of interest for
developing TD. Our final panel consisted of 48 tag SNPs.
Statistical analysis. In order to be more certain about
the validity of the results, we used two statistical approaches
to analyze the data. Both biostatisticians (MF and PP)
independently developed different strategies to account for
missing data and interactions between different SNPs. The
Hardy–Weinberg equilibrium test was applied to groups with
and without dyskinesia. Thereafter, the first biostatistician
used the more classical logistic regression and log-linear
regression approach. The second biostatistician used the
permutation tests and logic regression method.18 Because
the genotyping for GRIN2A and GRIN2B was definitely
hypothesis-driven, no correction for multiple testing was
necessary on the primary outcome measure. All calculations
were performed in the R statistical environment with the
SNPassoc19 and LogicReg18 package and basic R functions.
Results
In patients with neurological disorders (n¼ 143), permutation
tests indicated that potential associations existed between
LID and the candidate SNPs or combinations of SNPs. In
models focused on patients with diagnosed Parkinson’s
disease (n¼ 101), 9% of permutations yielded a deviance-
based score smaller than that obtained with the best-fitted
model. In models focused on patients with Parkinson’s
disease that displayed only SNPs of the GRIN2A gene,
4.8% of permutations yielded a smaller score; this indicated
possible associations between the GRIN2A SNPs and LID.
A subsequent Monte Carlo logic regression analysis revea-
led that two GRIN2A variants, rs7192557 and rs8057394,
were most frequently associated with LID observed in all
body locations (‘all locations’). It is important to notice that
rs7192557 is a tagging SNP for rs1969060, which was
previously associated with the age of dyskinesia onset
in,11,12 and that SNP rs8057394 was the other variant
associated with HD.13
In an alternative analytical approach, logistic regression
was used to test associations between SNPs and dyskinesia.
The results indicated that the same two SNPs mentioned
above had the highest significance. When the patient sample
was limited to patients with diagnosed Parkinson’s disease
(Supplementary Table 2), a higher odds ratio was observed
than that for the entire group of patients with neurological
disorders (n¼ 143). For example, the odds ratio for an
association between rs7192557 and the ‘all locations’ LID
was 3.21 (95% CI: 1.37–7.51,P¼ 0.0062) for patients diagnosed
with Parkinson’s disease, and 2.71 (95% CI: 1.35–5.46,
P¼ 0.0046) for the whole group of patients with neurological
disorders. For rs8057394, these figures were 3.59 (95%
CI: 1.48–8.71; P¼ 0.0033) and 2.86 (95% CI: 1.42–5.76,
Figure 1 Schematic model of the cortico-striatal-thalamic-cortical (formerly
extrapyramidal) circuits, including the indirect and direct pathways; ENK,
enkephalin; GPe, Globus pallidus, external segment; GPi, Globus pallidus, internal
segment; SNc, Substantia nigra, pars compacta; SNr, substantia nigra, pars
reticulata; SP/DYN, substance P/dynorphin; STh, subthalamic nucleus; D1, D2,
medium-sized spiny neurons with D1 or D2 receptors.
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P¼ 0.0028), respectively. These two SNPs were also signi-
ficantly (Po0.05) associated with the severity of LID.
Thus, two different statistical methods, the permutation
analysis with logic regression and the logistic regression
provided similar results.
In the patient population with psychiatric disorders, no
relationship could be demonstrated between dyskinesia and
the GRIN2A variants, rs7192557 and rs8057394. Moreover,
in this patient population, the two different statistical analysis
methods produced inconsistent results. Logic regression
revealed that the GRIN2B variant rs2192970 and the GRIN2A
variant rs1345423 were the most influential of the SNPs
tested; however, permutation tests showed almost no
association between the SNPs and the outcome. A logistic
regression analysis also identified these two SNPs, but only
rs1345423 consistently showed highly significant associa-
tions with the presence of TD and with the severity of TD.
Discussion
Our results showed that the susceptibility to LID was
associated with two NMDA receptor (GRIN2A) variants,
identified by SNPs rs7192557 and rs8057394, which were
previously found to be associated with the age of dyskinesia
onset in HD.11–13 We also found that the susceptibility to TD
was associated with two different GRIN2B and GRIN2A
variants identified by SNPs rs2192970 and rs1345423,
respectively. However, the latter associations were by far
less convincing. It should be emphasized that our hypothesis
only addressed a possible role for the previously identified
SNPs. We selected a panel of 48 SNPs in eight candidate
genes. These included 24 SNPs in the genes that encoded
GRIN2A and GRIN2B. Therefore, at least some associations
should be attributed to chance findings owing to multiple
testing. However, when truly associated, the GRIN2A
(rs1345423) and GRIN2B (rs2192970) variants are unlikely
to be related to the polymorphisms previously found in genetic
association studies in schizophrenia20 or theGRIN2B variants
that were previously studied in TD21 and LID.22
It should be noticed that limb-truncal and all locations LID
show an association with rs7192557 and rs8057394, and that
orofacial LID shows no association with any SNP at all. This
may correspond with the observation that in HD and LID often
large muscle groups are affected and in TD more subtle
movements are present, most often in the orofacial area.
An important weakness of our study is the restriction of the
patient population to Caucasians from Siberia in Russia. This
could also be considered as strength of the study as a more
homogenous sample was used. Nevertheless, the need for
replication of our findings in an independent patient sample is
obvious. In addition, the influence of gender and race should
be studied in more detail in a larger patient group. Moreover,
the measures to assess TD in general show important
limitations.15 However, the large number of studied psychia-
tric patients and our adaptations to the assessment scale give
our classification sufficient reliability.
Our results indicate that HD and LID, but not TD, may result
from the same biochemical processes involved in the
pathology of the extrapyramidal circuit. In HD, this process
was linked to NMDA receptor-induced excitotoxicity in the
striatal MSNs that form the indirect pathway.5–7 Accordingly,
this implies that LID may arise from damage to MSNs in the
indirect pathway. Our hypothesis is supported by the
pathological changes observed in HD, where damage only
occurs to MSNs in the indirect pathway.
In contrast, our results showed that TD was not associated
with the same NMDA receptor variants. However, antipsy-
chotic drugs are also known to affect MSNs that carry
dopamine D2 receptors in the indirect pathway.8 Therefore,
the MSNs in the indirect pathway may be involved in TD as
well, but through a different mechanism.
On the basis of our results for LID, we speculate that the
MSNs in the indirect pathway may be particularly susceptible
to excitotoxicity during long-term treatment with levodopa
owing to the same mechanism that results in progressive
degeneration of nigrostriatal dopaminergic neurons in Par-
kinson’s disease.23 A well-known theory states that Parkin-
son’s disease-induced degeneration is related to the
genetically-determined susceptibility of catecholamine-
expressing neurons to oxidative stress.23 Therefore, we
propose that long-term exposure to the catecholamines
derived from levodopa may cause the death of MSNs due to
a combination of increased susceptibility to oxidative stress
and the presence of a variant NMDA receptor that accelerates
excitotoxicity.
However, before the above hypothesis can be tested, it is
necessary to replicate our finding and to investigate the
function of the variant GRIN2A receptor gene in greater detail.
It should be established whether the variant NMDA receptor is
more active in inducing excitotoxicity and, in addition, whether
it is sensitive for NMDA antagonists (for example, memantine
or hemantane). It may then be possible to prevent LID
by blocking activation of these variant NMDA receptors.
Thus, these NMDA antagonists may also be an effective
prophylactic for preventing LID in patients that are prone to
excitotoxicity during levodopa treatment. Interestingly, the
NMDA antagonist amantadine is known to have acute effects
on LID,24 but memantine lacks this effects.25 This can be
explained by postulating NMDA antagonism primarily at direct
and indirect pathway MSNs, respectively.
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